Empowering research requires **seamless** delivery of **high quality data**. The WAYFIND–R® platform enables automation and **accelerates insights generation** from primary data collection to research–ready data.

**Title:** Empowering research with seamless data flow and research–ready, anonymised data in OMOP CDM: Learnings from the design of WAYFIND–R, a global precision oncology registry and research platform

**Background:** WAYFIND–R is a global precision oncology registry (NCT04529122) and has the aim to advance science and provide the scientific community worldwide with access to real-world data, enabling epidemiological and clinical research, and collaborations across research groups. The WAYFIND–R® Data Sharing and Collaboration Platform enables researchers to access anonymised clinico–genomic data from the registry transformed to the OMOP CDM within a secure research environment.

**Methods**

- Harmonised NICS Data
- Registry Clinical Data
- Ancillary Study Data (future release)
- Source Data Assessment and Documentation (WhiteRabbit, RabbitinAHat)
- Structural Mapping (R based scripts)
- Terminology Mapping (OHDSI Athena vocabularies in combination with R scripts)
- Data Quality (Data Quality Dashboard)
- Pseudonymised OMOP data
- Anonymisation
- OMOP Anonymised Data

**Outcomes**

- Researchers able to access quality OMOP anonymised aggregate and individual–level data from registry
- Automation of concept mapping simplifies review process on an ongoing basis
- Defined data quality processes allow for routine checking of data and actions for each data release cycle. For example queries raised within clinical database
- ETL automation ensures consistency and reproducible output
- Changes to the structure registry clinical database require ongoing assessments to determine impact to data and platform
- Implementation of cohort definition within platform

**Opportunities for Collaboration**

- Gene and biomarker ontologies
- Oncology extension
- Registry studies – our learnings

**Acknowledgements:**

We thank the patients and their families who take part in WAYFIND–R, as well as the staff, research coordinators, and investigators at each participating institution.

---

Tom Stone¹, Yuri Pyatkin², Ana Ferro¹, Dimitar Toshev²

¹ Roche Products Limited, Welwyn Garden City, UK; ² F. Hoffmann–La Roche Ltd, Basel, Switzerland